Emergent BioSolutions (NYSE: EBS) might disagree after its highly publicized COVID-19 vaccine manufacturing problems. In this Motley Fool Live video recorded on June 23, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not Emergent BioSolutions can recover from its recent blunders. Brian Orelli: Yes, they can fix the issues that they had with the manufacturing and get better management in there to make sure that they're following all the FDA rules and good manufacturing practices.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting